<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532153</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001783</org_study_id>
    <nct_id>NCT02532153</nct_id>
  </id_info>
  <brief_title>The Impact of Ketamine on the Reward Circuitry of Suicidal Patients</brief_title>
  <official_title>The Impact of Ketamine on the Reward Circuitry of Suicidal Patients: An MRI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every 40 seconds, someone in the world dies by suicide. There is a lack of effective and safe&#xD;
      antisuicidal agents for preventing suicide attempts. This leads to the immense worldwide&#xD;
      individual, financial, and societal burden of suicide-which is projected to rise in the&#xD;
      coming decades-supporting the need for antisuicidal treatments.&#xD;
&#xD;
      This treatment gap may be filled through understanding the neurobiology of suicide, which can&#xD;
      guide the development of targeted antisuicidal treatments. Though some research has examined&#xD;
      the neurobiology of suicidal ideation in the context of depression-implicating the orbital&#xD;
      frontal cortex, anterior cingulate cortex, and striatum-the underlying pathophysiology and&#xD;
      neurobiology of suicidal ideation as a separate construct from depression remains largely&#xD;
      unknown. Therefore, the investigators propose to study the neurocircuitry of suicidal&#xD;
      thoughts, regardless of whether or not depression is present.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding.&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 2017</start_date>
  <completion_date type="Actual">February 28, 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Suicide Rating Scale from 1-5; higher numbers indicate increased suicidal thinking</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Suicidal Ideation</condition>
  <condition>Suicide</condition>
  <arm_group>
    <arm_group_label>Open-Label Ketamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>Single open-label infusions</description>
    <arm_group_label>Open-Label Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will:&#xD;
&#xD;
          1. be ≥18 years old,&#xD;
&#xD;
          2. read, understand, and provide written informed consent,&#xD;
&#xD;
          3. have suicidal ideation for ≥ 2 months, per the Columbia Suicide Severity Rating Scale&#xD;
             (C-SSRS),&#xD;
&#xD;
          4. be on a stable psychiatric medication regimen for ≥28 days,&#xD;
&#xD;
          5. maintain a treating doctor who is in agreement with study participation, and aware of&#xD;
             the safety plan in the protocol,&#xD;
&#xD;
          6. have a reliable chaperone accompany them home following the completion of the ketamine&#xD;
             infusion day,&#xD;
&#xD;
          7. be generally healthy, as assessed by medical history, physical examination (including&#xD;
             vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),&#xD;
&#xD;
          8. be of non-childbearing potential or use of an acceptable form of birth control&#xD;
             (females only), and&#xD;
&#xD;
          9. be right handed.&#xD;
&#xD;
        Healthy Controls will:&#xD;
&#xD;
          1. be ≥18 years old,&#xD;
&#xD;
          2. read, understand, and provide written informed consent,&#xD;
&#xD;
          3. have a negative pregnancy test on the morning of the MRI (females only).&#xD;
&#xD;
          4. be right handed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if any of the following criteria are met:&#xD;
&#xD;
          1. delirium or dementia diagnosis,&#xD;
&#xD;
          2. unstable medical illness or clinically significant laboratory results,&#xD;
&#xD;
          3. history of clinically significant cardiovascular disease or electrocardiogram (EKG)&#xD;
             findings, or medical conditions that put the patient at risk for possible cardiac side&#xD;
             effects or alter brain morphology (e.g., diabetes, hypertension, traumatic brain&#xD;
             injury), even if well controlled on medications,&#xD;
&#xD;
          4. history of multiple adverse drug reactions,&#xD;
&#xD;
          5. active substance use disorders (except nicotine and caffeine) within the past six&#xD;
             months, positive urine toxicology screen, or past history of ketamine/PCP abuse,&#xD;
&#xD;
          6. requirement of excluded medications that may interact with ketamine (e.g., narcotics,&#xD;
             barbiturates, sedatives, theophylline, or St. John's Wort),&#xD;
&#xD;
          7. BMI &gt;35,&#xD;
&#xD;
          8. pregnancy, breastfeeding, or unacceptable means of birth control (females only)&#xD;
&#xD;
          9. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants&#xD;
             (e.g., heart pacemaker, aneurysm clips)),&#xD;
&#xD;
         10. concurrent participation in other research studies.&#xD;
&#xD;
        Healthy controls will be excluded if any of the following criteria are met:&#xD;
&#xD;
          1. current or past Axis I diagnosis, including alcohol or substance abuse or dependence&#xD;
             diagnosis (except for nicotine or caffeine) and suicidal thoughts/attempts,&#xD;
&#xD;
          2. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants&#xD;
             (e.g., heart pacemaker, aneurysm clips)),&#xD;
&#xD;
          3. presence of medical illness likely to alter brain morphology and/or physiology (e.g.,&#xD;
             diabetes) even if controlled by medications,&#xD;
&#xD;
          4. requirement of excluded medications that may interact with ketamine (e.g., narcotics,&#xD;
             barbiturates, benzodiazepines, sedatives, theophylline, or St. John's Wort),&#xD;
&#xD;
          5. presence of psychiatric disorders in first-degree relatives,&#xD;
&#xD;
          6. pregnancy, breastfeeding, or unacceptable means of birth control (females only), or&#xD;
&#xD;
          7. BMI &gt;35.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn Ionescu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depressionmgh.org/our-studies</url>
    <description>MGH Depression Clinical and Research Program</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dawn F Ionescu</investigator_full_name>
    <investigator_title>Assistant in Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Suicidal Ideation</keyword>
  <keyword>Suicide</keyword>
  <keyword>Suicidal Thoughts</keyword>
  <keyword>Depression</keyword>
  <keyword>Ketamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

